1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021

Oncology/Anti-cancer drugs are used for treating various cancer types for improving and prolonging a patients survival time. Biological drugs, based on monoclonal antibodies (mAbs) would emerge as a preferred option for treating various cancer types, especially blood cancer (leukaemia). The rising incidence and prevalence of various cancer types, new cancer treatments and growing importance of biological and targeted drug therapies, are driving the market growth of LAMEA oncology/anti-cancer drugs. In addition, increasing demand of anti-cancer drugs for the treatment of ageing population, rising government funds and improved treatment results, are major factors boosting the market growth. However, the high cost involved in new drug development, coupled with threat of failure and adverse effects associated with anti-cancer drugs therapies, would restrain the growth of the LAMEA market. Moreover, accessibility of anti-cancer drugs incurred by high cost, is a major challenge that is expected to further impede the performance of anti-cancer drugs in LAMEA region. Nevertheless, commercialization of advanced therapeutics, such as targeted therapies and immunotherapies (biologic therapies) would reduce the negative influence of restraints and fuel the market growth.The LAMEA oncology drugs market is segmented into therapeutic modalities, cancer types and countries. Therapeutic modalities segment is further categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), hormonal therapy and others. The LAMEA oncology drugs market is expected to reach $17,072.2 million by 2021. Patent expiration of key anti-cancer drugs such as Herceptin (Patent Expiration: EU-2014; US-2019), Erbitux (Patent Expiration: EU-2014; US-2016), Rituxan (Patent Expiration: EU-2013; US-2018) and Avastin (Patent Expiration: EU-2018; US-2019), is expected to boost the growth of cancer biosimilars market by 2021. Further, the biological therapy is the fastest growing segment at a CAGR of 12.2%, throughout the analysis period, on account of high efficacy and target specific action. Moreover, blood cancer drugs market was the largest revenue generating application segment in 2015, owing to the high cost of drugs (immunotherapies), used for the treatment of blood cancer.Based on countries the LAMEA region is segmented into nine countries named Brazil, Argentina, Nigeria, South Africa, Iraq, Iran, Algeria, Saudi Arabia and Egypt. Brazil dominates the LAMEA market closely followed by Argentina, owing to rising incidence of cancer, high expenditure and gross national income (GNI) of Brazil specifically. In addition, LAMEA market is poised to grow at a promising CAGR of 8.6% during the forecast period. This high growth rate is majorly attributed to the increasing awareness towards advanced therapies, namely immunotherapies and increase in per capita healthcare spending.The key companies profiled in the report include Amgen Inc., AstraZeneca Plc., Roche Diagnostics, GlaxoSmithKline PLC, Merck & Co., Novartis AG, AbbVie Inc. Sanofi, EIMC United Pharmaceuticals (EUP) and Actavis plc.

KEY BENEFITS
:The report provides quantitative analysis of the current market and estimations through 2014-2021 that assists in identifying the prevailing market opportunities.The report helps in understanding the strategies adopted by various companies for gaining market share in the anti-cancer drugs market.The report provides a comprehensive analysis of factors that drive and restrict the growth of the LAMEA anti-cancer drugs market.Market conditions of anti-cancer drugs market across LAMEA region are comprehensively analyzed.Competitive intelligence highlights the business practices followed by leading market players across various geographies.SWOT analysis enables to study the internal environment of the leading companies for strategy formulation.LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET KEY SEGMENTS:LAMEA oncology/anti-cancer drugs market is segmented into therapeutic modalities, cancer types and countries.By Therapeutic modalitiesChemotherapyTargeted TherapyImmunotherapy (Biologic Therapy)Hormonal TherapyOthersBy Cancer TypesBlood CancerBreast CancerGastrointestinal CancerRespiratory/Lung CancerSkin CancerOther CancersBy CountriesBrazilArgentinaNigeriaSouth AfricaIraqIranAlgeriaSaudi ArabiaEgyptOther LAMEA countries

Table Of Contents

LAMEA Oncology/Anti-cancer drugs Market - Opportunities and Forecasts, 2014 - 2021
CHAPTER 1 INTRODUCTION1.1 Report description1.2 Key benefits1.3 Key market segment1.4 Research methodology1.4.1 Secondary research1.4.2 Primary research1.4.3 Analyst tools and modelsCHAPTER 2 EXECUTIVE SUMMARYCHAPTER 3 MARKET OVERVIEW3.1 Market definition and scope3.2 Development of novel immuno-oncology drug products3.3 Key findings3.3.1 Top impacting factors3.3.2 Top investment pockets3.3.3 Top winning strategies3.4 Government regulations3.4.1 Regulations in Middle East3.5 Reimbursement scenario3.5.1 Reimbursement in Middle East3.6 Drivers3.6.1 Rising incidence and prevalence of various cancer types3.6.2 Growing importance of biological and targeted drug therapies3.6.3 Increasing funding and aid from public and private sector3.7 Restraints3.7.1 High cost of drug development and threat of failure3.7.2 Adverse effects of cancer drug therapy3.8 Opportunities3.8.1 Advancement of anti-cancer drugs research3.8.2 Healthcare and medical awarenessCHAPTER 4 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES,2014-20214.1 Chemotherapy4.1.1 Market size and forecast4.2 Targeted therapy4.2.1 Market size and forecast4.3 Immunotherapy (biologics therapy)4.3.1 Market size and forecast4.4 Hormonal therapy4.4.1 Market size and forecast4.5 Others4.5.1 Market size and forecastCHAPTER 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES,2014-20215.1 Blood cancer5.1.1 Market size and forecast5.2 Breast cancer5.2.1 Market size and forecast5.3 Gastrointestinal cancer5.3.1 Market size and forecast5.4 Prostate cancer5.4.1 Market size and forecast5.5 Respiratory/lung cancer5.5.1 Market size and forecast5.6 Skin cancer5.6.1 Market size and forecast5.7 Other cancers5.7.1 Trends in treatment of other cancer types5.7.2 Market size and forecastCHAPTER 6 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES,2014-20216.1 Brazil6.1.1 Market size and forecast6.2 Argentina6.2.1 Market size and forecast6.3 Nigeria6.3.1 Market size and forecast6.4 South Africa6.4.1 Market size and forecast6.5 Iraq6.5.1 Market size and forecast6.6 Iran6.6.1 Market size and forecast6.7 Algeria6.7.1 Market size and forecast6.8 Saudi Arabia6.8.1 Market size and forecast6.9 Egypt6.9.1 Market size and forecast6.10 Other LAMEA countries6.10.1 Market size and forecastCHAPTER 7 COMPANY PROFILES7.1 Amgen Inc.7.1.1 Company overview7.1.2 Business performance7.1.3 Operating business segment overview7.1.4 Key strategies and development7.1.5 SWOT analysis7.2 AstraZeneca PLC.7.2.1 Company overview7.2.2 Business performance7.2.3 Key strategies and development7.2.4 SWOT analysis and strategic conclusions7.3 Roche Diagnostics7.3.1 Company overview7.3.2 Operating business segment overview7.3.3 Business performance7.3.4 Key strategies moves and development7.3.5 SWOT analysis7.4 GlaxoSmithKline PLC7.4.1 Company overview7.4.2 Operating business segment overview7.4.3 Business performance7.4.4 Key strategies move and development7.4.5 SWOT Analysis7.5 Merck andamp; Company7.5.1 Company overview7.5.2 Operating business segment overview7.5.3 Business performance7.5.4 Key strategies move and development7.5.5 SWOT analysis7.6 Novartis AG7.6.1 Company overview7.6.2 Operating business segment overview7.6.3 Business performance7.6.4 Key strategies move and development7.6.5 SWOT analysis7.7 AbbVie Inc.7.7.1 Company overview7.7.2 Business performance7.7.3 Strategic moves and developments7.7.4 SWOT analysis7.8 Sanofi7.8.1 Company overview7.8.2 Operating business segment overview7.8.3 Business performance7.8.4 Key strategies move and development7.8.5 SWOT analysis7.9 EIMC United Pharmaceuticals (EUP)7.9.1 Company overview7.9.2 Operating business segment overview7.9.3 Key strategies move and development7.9.4 SWOT analysis7.10 Actavis plc7.10.1 Company overview7.10.2 Operating business segment overview7.10.3 Business performance7.10.4 Key strategies move and development7.10.5 SWOT analysisList of FiguresFIG. 1 TOP FACTORS IMPACTING ANTI-CANCER DRUGS MARKET (2014-2021)FIG. 2 TOP INVESTMENT POCKETS OF ONCOLOGY/ANTI-CANCER DRUGS MARKET (2014)FIG. 3 TOP WINNING STRATEGIES FOR GLOBAL CANCER DRUG MARKET (2011-2015)FIG. 4 TOP WINNING STRATEGIES BY SUBTYPE (2011-2015)FIG. 5 PERCENTAGE (%) OF ALL NEW CANCERS CASES DIAGNOSED IN 2012FIG. 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)FIG. 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)FIG. 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)FIG. 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)FIG. 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)FIG. 11 LAMEA BLOOD CANCER DEATH RATE (PER 100,000), (2014)FIG. 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)FIG. 13 LAMEA BREAST CANCER DEATH RATE (PER 100,000), 2014FIG. 14 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)FIG. 15 LAMEA GASTROINTESTINAL CANCER DEATH RATE (PER 100,000), 2014FIG. 16 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)FIG. 17 LAMEA PROSTATE CANCER DEATH RATE (PER 100,000), 2014FIG. 18 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)FIG. 19 LAMEA RESPIRATORY/LUNG CANCER DEATH RATE (PER 100,000), 2014FIG. 20 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)FIG. 21 LAMEA SKIN CANCER DEATH RATE (PER 100,000), 2014FIG. 22 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)FIG. 23 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)FIG. 24 AMGEN INC. REVENUE BY GEOGRAPHY (2014)FIG. 25 AMGEN INC. REVENUE BY PRODUCT PORTFOLIO (2014)FIG. 26 SWOT ANALYSIS OF AMGEN INC.FIG. 27 FINANCIAL REVENUES BY GEOGRAPHY (2014)FIG. 28 FINANCIAL REVENUES BY YEAR, 2014 ($MILLION)FIG. 29 SWOT ANALYSIS AND STRATEGIC CONCLUSIONSFIG. 30 ROCHE DIAGNOSTICS BY BUSINESS UNITS (2014)FIG. 31 SWOT ANALYSIS OF ROCHE DIAGNOSTICSFIG. 32 GLAXOSMITHKLINE PLC REVENUE BY GEOGRAPHY (2014)FIG. 33 GLAXOSMITHKLINE PLC REVENUE BY BUSINESS SEGMENTS (2014)FIG. 34 SWOT ANALYSIS OF GLAXOSMITHKLINE PLCFIG. 35 MERCK andamp; CO. REVENUE BY GEOGRAPHY (2014)FIG. 36 SWOT ANALYSIS OF MERCK andamp; COMPANYFIG. 37 NOVARTIS AG REVENUE BY GEOGRAPHY (2014)FIG. 38 NOVARTIS AG REVENUE BY BUSINESS SEGMENTS (2014)FIG. 39 SWOT ANALYSIS OF NOVARTIS AGFIG. 40 NET SALES REVENUES OF ABBVIE BY GEOGRAPHY, 2014 ($MILLION)FIG. 41 SWOT ANALYSIS OF ABBVIEFIG. 42 SANOFI REVENUE BY GEOGRAPHIES (2014)FIG. 43 SANOFI REVENUE BY BUSINESS SEGMENTS (2014)FIG. 44 SWOT ANALYSIS OF SANOFIFIG. 45 SWOT ANALYSIS OF EUPFIG. 46 ACTAVIS CORPORATION REVENUE BY PRODUCT SALES (2014)FIG. 47 SWOT ANALYSIS OF ACTAVIS PLCList of TablesTABLE 1 INTERNATIONAL DISEASE CLASSIFICATION CODES AND DESCRIPTION OF CANCER DIAGNOSESTABLE 2 LAMEA ESTIMATED INCIDENCE AND PREVALENCE OF ALL CANCER TYPES, (2012)TABLE 3 LIST OF BIOLOGICAL AND TARGETED DRUGS WITH THEIR REVENUE IN 2013 ($MILLION)TABLE 4 LIST OF COLLABORATIONS AND ACQUISITIONS FOR DEVELOPMENT OF CANCER DRUGSTABLE 5 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY THERAPEUTIC MODALITIES, 2014 2021 ($MILLION)TABLE 6 LAMEA CHEMOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)TABLE 7 LAMEA TARGETED THERAPY DRUGS MARKET, 2014 2021 ($MILLION)TABLE 8 LAMEA IMMUNOTHERAPY DRUGS MARKET, 2014 2021 ($MILLION)TABLE 9 LAMEA HORMONAL THERAPY DRUGS MARKET, 2014 2021 ($MILLION)TABLE 10 LAMEA OTHER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 11 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY CANCER TYPES, 2014 2021 ($MILLION)TABLE 12 LAMEA BLOOD CANCER MARKET, 2014 2021 ($MILLION)TABLE 13 LAMEA BREAST CANCER MARKET, 2014 2021 ($MILLION)TABLE 14 LAMEA GASTROINTESTINAL CANCER MARKET, 2014 2021 ($MILLION)TABLE 15 LAMEA PROSTATE CANCER MARKET, 2014 2021 ($MILLION)TABLE 16 LAMEA RESPIRATORY/LUNG CANCER MARKET, 2014 2021 ($MILLION)TABLE 17 LAMEA SKIN CANCER MARKET, 2014 2021 ($MILLION)TABLE 18 LAMEA OTHER CANCER MARKET, 2014 2021 ($MILLION)TABLE 19 LAMEA ONCOLOGY/ANTI-CANCER DRUGS MARKET BY COUNTRIES, 2014 2021 ($MILLION)TABLE 20 BRAZIL ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 21 ARGENTINA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 22 NIGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 23 SOUTH AFRICA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 24 IRAQ ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 25 IRAN ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 26 ALGERIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 27 SAUDI ARABIA ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 28 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 29 EGYPT ONCOLOGY/ANTI-CANCER DRUGS MARKET, 2014 2021 ($MILLION)TABLE 30 AMGEN INC. SNAPSHOTTABLE 31 ASTRAZENECA SNAPSHOTTABLE 32 ROCHE DIAGNOSTICS SNAPSHOTTABLE 33 ROCHE DIAGNOSTICS OPERATING SEGEMENTSTABLE 34 GLAXOSMITHKLINE PLC SNAPSHOTTABLE 35 GLAXOSMITHKLINE PLC OPERATING SEGEMENTSTABLE 36 MERCK andamp; COMPANY SNAPSHOTTABLE 37 MERCK andamp; CO. OPERATING SEGEMENTSTABLE 38 NOVARTIS AG SNAPSHOTTABLE 39 NOVARTIS AG OPERATING SEGEMENTSTABLE 40 ABBVIE INC. SNAPSHOTTABLE 41 SANOFI SNAPSHOTSTABLE 42 SANOFI OPERATING SEGEMENTSTABLE 43 EIMC UNITED PHARMA SNAPSHOTSTABLE 44 ACTAVIS CORPORATION SNAPSHOTS

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Europe Cancer Diagnostic Testing Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology

2016 Europe Cancer Diagnostic Testing Analyzers and Reagents in 28 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology

  • $ 34500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 28-country survey from VPGMarketResearch.com contains over 925 pages and 366 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

Europe Cancer Diagnostics Market 2017-2021:  France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies

Europe Cancer Diagnostics Market 2017-2021: France, Germany, Italy, Spain, UK--Opportunities for Instrument and Reagent Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies

  • $ 12800
  • Industry report
  • December 2016
  • by Venture Planning Group

Complete report $19,700.DataPack (test volumes, sales forecasts, supplier shares) $12,800. Summary This comprehensive five-country report contains 820 pages, 320 tables, and presents analysis of the majo ...


Download Unlimited Documents from Trusted Public Sources

Hormone and Therapy Market in Pakistan and the US

  • January 2017
    7 pages
  • Hormone  

    Therapy  

    Diabetes  

  • Pakistan  

    United States  

View report >

Insulin Market and Diabetes Statistics in the US

  • January 2017
    8 pages
  • Insulin  

    Antidiabetics  

    Diabetes  

  • United States  

View report >

Anti-Infective Market and Infectious Disease Statistics in the US

  • January 2017
    52 pages
  • Anti-Infective  

    Infectious Dise...  

    Vaccine  

  • United States  

View report >

Therapy Market

1 day ago

Related Market Segments :

Cancer

ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.